We established models of cancer-related anemia in mice from subcutaneous inoculation of two IL-6-producing cancer cell lines, human lung cancer cell line LC-06-JCK and murine colon26 clone 5 colon cancer cells. In both models, elevated levels of IL-6 were detected in sera and hemoglobin levels significantly decreased compared with non-tumor-bearing mice. In the LC-06-JCK model, serum albumin levels also decreased with elevated levels of human IL-6 in sera. On the other hand, serum levels of EPO increased, although anemia developed and did not improve. The development of cancer-related anemia was prevented by the administration of a rat anti-mouse IL-6 receptor antibody, MR16-1, in the LC-06-JCK model. It is therefore suggested that IL-6 causes anemia independent of a reduction in EPO levels. Our preclinical models should be useful for exploring new modalities for the treatment of cancer-related anemia.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2220/biomedres.30.47 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Macrocytic anemia, kidney dysfunction, and mortality in general population: Japan specific health checkup study.
Sci Rep
December 2024
Steering Committee of Research on Design of the Comprehensive Health Care System for Chronic Kidney Disease (CKD) Based on the Individual Risk Assessment by Specific Health Check, Fukushima, Japan.
Anemia and chronic kidney disease (CKD), which worsen bidirectionally, are associated with mortality in older adults. This study aimed to examine the association between CKD and the type of anemia and its impact on mortality in the general population. Data from a nationwide database of 203,280 individuals who participated in the annual "Specific Health Check and Guidance in Japan" evaluation between 2008 and 2011 were used.
View Article and Find Full Text PDFFunctionalized Iron Oxide Nanoparticles for Both Dual-Modal Imaging and Erythropoiesis.
ACS Appl Mater Interfaces
December 2024
Guangdong Provincial Key Laboratory of Advanced Biomaterials, Shenzhen Key Laboratory of Smart Healthcare Engineering, Department of Biomedical Engineering, Southern University of Science and Technology, No. 1088 Xueyuan Road, Nanshan District, Shenzhen, Guangdong 518055, P. R. China.
Cancer-related anemia (CRA), a complication of cancer, is considered the primary cause of high mortality for cancer patients. Safe and effective theranostics are desirable for realizing the high diagnostic accuracy of tumors and ameliorating CRA in the clinic. However, the available theranostics do not support dual-modal imaging and the amelioration of CRA at the same time.
View Article and Find Full Text PDFResistance training for fatigue in people with cancer.
Cochrane Database Syst Rev
November 2024
Cochrane Haematology, Institute of Public Health, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
Background: Cancer-related fatigue (CRF) is one of the most common symptoms associated with cancer and its treatment. Different types of exercise have demonstrated beneficial effects on CRF. Previous evidence syntheses provided promising but inconclusive results when focusing on the effects of resistance training.
View Article and Find Full Text PDFPrevalence of cancer-related fatigue, associated factors and adult cancer patients' experiences at Hawassa University Comprehensive Specialized Hospital in Ethiopia: a mixed methods study.
Front Oncol
November 2024
Department of Physiology, School of Medicine, College of Medicine and Health Science, University of Gondar, Gondar, Ethiopia.
Purpose: Cancer-related fatigue is a prevalent issue affecting 50-90% of cancer patients who experience fatigue at diagnosis, during therapy, and often for months or years after the completion of therapy. This study aimed to explore the prevalence of cancer-related fatigue, associated factors, and adult cancer patients' experiences at Hawassa University Comprehensive Specialized Hospital in Ethiopia.
Methods: A mixed-method study was conducted from February 25 to May 15, 2023, via cross-sectional descriptive and phenomenological approaches.
Efficacy and outcome analysis: monotherapy and combination therapy of S-1 for patients with advanced non-small cell lung cancer.
J Thorac Dis
October 2024
Department of Medical Oncology, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, China.
Background: Lung cancer is the leading cause of cancer-related mortality worldwide. S-1, a fluorouracil derivative known for its efficacy and minimal adverse effects in various solid tumors, offers hope for advanced non-small cell lung cancer (NSCLC) patients. This study conducted a retrospective, single-center analysis to investigate the effectiveness and safety of S-1 monotherapy and combination therapy as second-line or subsequent treatment for advanced NSCLC.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!